Cagnoni Joins CRISPR Tx Board, Coles Named Chairman

Xconomy Boston — 

Cambridge, MA, and Basel-based CRISPR Therapeutics has bolstered its board of directors. Yumanity Therapeutics CEO and former Onyx Pharmaceuticals CEO Tony Coles—who was already on CRISPR’s board—was named chairman, replacing Versant Ventures managing director Brad Bolzon. Pablo Cagnoni, another Onyx veteran and currently the president and CEO of South San Francisco, CA, startup Tizona Therapeutics, also joined CRISPR’s board.